London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami
Globe Newswire15-04-2024, 19:00
UPDATE: THE COVID-19 DETECTION FOUNDATION (dba VIRUFY) and 8-03-2023, 21:22